Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2018 251 B
EBIT 2018 -
Net income 2018 38 761 M
Finance 2018 134 B
Yield 2018 1,91%
Sales 2019 272 B
EBIT 2019 -
Net income 2019 44 972 M
Finance 2019 144 B
Yield 2019 1,97%
P/E ratio 2018 33,66
P/E ratio 2019 27,25
EV / Sales2018 5,23x
EV / Sales2019 4,78x
Capitalization 1 443 B
More Financials
Company
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of pharmaceutical and diagnostic reagents focusing on prescription pharmaceuticals.Its products include respiratory, digestive, urinary, chemotherapy, hormone, vitamins, and metabolic drugs.The company was founded by Ichibei... 
More about the company
Surperformance© ratings of ONO PHARMACEUTICAL CO., LT
Trading Rating : Investor Rating :
More Ratings
Latest news on ONO PHARMACEUTICAL CO., LT
09/22 ONO PHARMACEUTICAL : Receives Approval for OPDIVO® (Nivolumab) Intravenous Infus..
09/20 ONO PHARMACEUTICAL : Opdivo® (Nivolumab) Intravenous Infusion Approved for Expan..
09/19 ONO PHARMACEUTICAL : Opdivo® (Nivolumab) Intravenous Infusion Approved for Expan..
09/14 ONO PHARMACEUTICAL : Array BioPharma Announces FDA Acceptance for Review of Bini..
09/13 ONO PHARMACEUTICAL : Phase 3 BEACON CRC Safety Lead-In Results in BRAF-Mutant Co..
09/13 ONO PHARMACEUTICAL : Phase 3 COLUMBUS Part 2 Results in BRAF-Mutant Melanoma Pre..
09/12 EISAI : Conclusion of development collaboration agreement for lenvima and opdivo..
09/12 ONO PHARMACEUTICAL : Opdivo Plus Yervoy Combination Demonstrated Superior Overal..
09/11 ONO PHARMACEUTICAL : Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Su..
09/11 ONO PHARMACEUTICAL : Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survi..
More news
Sector news : Generic Pharmaceuticals
09:36a SHANGHAI PHARMACEUTICALS : CVC, others explore sale of drugmaker Alvogen - Bloom..
09/25 European shares stay near highs as Merkel hangs on to power
09/25 Lufthansa names former CFO Kley as new chairman
09/25 ALLERGAN : boosts shares with $2 billion buyback
09/24 SAP to buy customer management software firm Gigya
More sector news : Generic Pharmaceuticals
Latest Tweets
09/01Ono Pharmaceutical : Announces Status of Acquisition of Own Shares (150KB)  
06/29ONO PHARMACEUTICAL : Notice of Resolutions Passed at The 69th Ordinary Genera.. 
06/29ONO PHARMACEUTICAL : Notice Concerning Issuance of Stock Options (Stock Acqui.. 
06/13ONO PHARMACEUTICAL : Announcement on Acquisition and Retirement of Own Shares.. 
05/31$ARRY (+3.1% pre) Array BioPharma & Ono Pharmaceutical Announce A License..
2
More tweets
Qtime:22
News from SeekingAlpha
06/22 Only Bristol Bucks Big Pharma's Drive For External Reliance
06/02 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 2, 2017
05/31 Array out-licenses binimetinib and encorafenib to Ono Pharma for Japan and So..
05/10 BRISTOL-MYERS SQUIBB : A Deep Dive Finds Some Pearls
01/23 Bristol Catches A Break At Last
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Technical analysis trends ONO PHARMACEUTICAL CO., LT
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 2 673  JPY
Spread / Average Target 9,1%
EPS Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Shozo Matsuoka Executive Officer & Manager-Medical Affairs
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director, EVP & General Manager-Development
Isao Ono Director & Managing Executive Officer
Sector and Competitors